ES2986021T3 - Proteína factor 1 para la utilización en el tratamiento o prevención de enfermedades - Google Patents

Proteína factor 1 para la utilización en el tratamiento o prevención de enfermedades Download PDF

Info

Publication number
ES2986021T3
ES2986021T3 ES14700872T ES14700872T ES2986021T3 ES 2986021 T3 ES2986021 T3 ES 2986021T3 ES 14700872 T ES14700872 T ES 14700872T ES 14700872 T ES14700872 T ES 14700872T ES 2986021 T3 ES2986021 T3 ES 2986021T3
Authority
ES
Spain
Prior art keywords
protein
factor
seq
cardiomyopathy
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14700872T
Other languages
English (en)
Spanish (es)
Inventor
Kai Christoph Wollert
Mortimer Korf-Klingebiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Hochschule Hannover
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Application granted granted Critical
Publication of ES2986021T3 publication Critical patent/ES2986021T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
ES14700872T 2013-01-17 2014-01-16 Proteína factor 1 para la utilización en el tratamiento o prevención de enfermedades Active ES2986021T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151593 2013-01-17
PCT/EP2014/050788 WO2014111458A2 (en) 2013-01-17 2014-01-16 Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Publications (1)

Publication Number Publication Date
ES2986021T3 true ES2986021T3 (es) 2024-11-08

Family

ID=47559322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14700872T Active ES2986021T3 (es) 2013-01-17 2014-01-16 Proteína factor 1 para la utilización en el tratamiento o prevención de enfermedades

Country Status (16)

Country Link
US (1) US10369198B2 (enExample)
EP (2) EP3747457A3 (enExample)
JP (4) JP6809789B2 (enExample)
CN (6) CN110903378A (enExample)
CA (1) CA2898128A1 (enExample)
DK (1) DK2945642T3 (enExample)
ES (1) ES2986021T3 (enExample)
FI (1) FI2945642T3 (enExample)
HR (1) HRP20240623T1 (enExample)
HU (1) HUE068364T2 (enExample)
LT (1) LT2945642T (enExample)
PL (1) PL2945642T3 (enExample)
PT (1) PT2945642T (enExample)
RS (1) RS65553B1 (enExample)
SI (1) SI2945642T1 (enExample)
WO (1) WO2014111458A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014111458A2 (en) * 2013-01-17 2014-07-24 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
CA2956256A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10435757B1 (en) 2016-06-15 2019-10-08 University Of South Florida Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
CN108802372B (zh) * 2018-06-19 2021-05-11 上海伦泽生物科技有限公司 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒
CN115698048A (zh) 2020-01-21 2023-02-03 勃林格殷格翰国际有限公司 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子
CN114149500B (zh) * 2020-09-07 2023-12-01 复旦大学附属华山医院 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用
CN114149498B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
CN114149499B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
EP4267594A1 (en) 2020-12-23 2023-11-01 Boehringer Ingelheim International GmbH Viral capsid proteins with specificity to heart tissue cells
AU2022307365A1 (en) * 2021-07-08 2024-02-01 Tenaya Therapeutics, Inc. Optimized expression cassettes for gene therapy
KR20250031229A (ko) 2022-06-03 2025-03-06 베링거 인겔하임 인터내셔날 게엠베하 골수 유래된 성장 인자의 재조합 발현
WO2024052563A1 (en) 2022-09-08 2024-03-14 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating cardiogenic shock
TW202528339A (zh) 2023-09-01 2025-07-16 德商百靈佳殷格翰國際股份有限公司 用於治療或預防肝臟病症之骨髓源性生長因子
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
US20250186549A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor
CN120738287A (zh) * 2025-07-03 2025-10-03 广州医科大学附属妇女儿童医疗中心 急性低灌注动物模型的构建方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
JP2002500502A (ja) 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成ｃ型肝炎遺伝子
JP2001506484A (ja) * 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
CA2265923A1 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center Human proteins having secretory signal sequences and dnas encoding these proteins
WO2002008284A2 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2000073445A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3)
PL334902A1 (en) * 1997-01-29 2000-03-27 Cornell Res Foundation Inc Repeatable local delivery of adenoviral vector in order to induce angiogenesis
DE60045243D1 (de) 1999-05-26 2010-12-30 Next Biomed Technologies Nbt Oy VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN
WO2001012669A1 (en) * 1999-08-16 2001-02-22 Universita' Degli Studi Di Siena Vegf-d and angiogenic use thereof
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
WO2004060867A2 (en) 2003-01-02 2004-07-22 Timothy Kirk Gallaher Secreted protein factor and cell membrane-bound splice variant
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US8486438B2 (en) 2004-01-29 2013-07-16 Brown University Methods for progenitor cell recruitment and isolation
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US20080004232A1 (en) * 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2130547A1 (en) * 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
PE20121647A1 (es) * 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
US8735342B2 (en) 2010-01-27 2014-05-27 Neumedicines, Inc. Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
KR20120095063A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
WO2014111458A2 (en) * 2013-01-17 2014-07-24 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Also Published As

Publication number Publication date
EP2945642A2 (en) 2015-11-25
JP2025143268A (ja) 2025-10-01
DK2945642T3 (da) 2024-05-27
HRP20240623T1 (hr) 2024-08-02
CN110922468A (zh) 2020-03-27
CN110903378A (zh) 2020-03-24
HUE068364T2 (hu) 2024-12-28
US10369198B2 (en) 2019-08-06
LT2945642T (lt) 2024-06-25
JP2016506911A (ja) 2016-03-07
WO2014111458A2 (en) 2014-07-24
EP3747457A2 (en) 2020-12-09
CN110922468B (zh) 2024-09-24
CN110922467A (zh) 2020-03-27
CN111100197B (zh) 2024-11-15
CN104968361B (zh) 2019-12-17
SI2945642T1 (sl) 2024-07-31
CN110894226A (zh) 2020-03-20
PT2945642T (pt) 2024-05-27
EP2945642B1 (en) 2024-02-21
JP2020203894A (ja) 2020-12-24
JP7685737B2 (ja) 2025-05-30
CN104968361A (zh) 2015-10-07
JP2023025005A (ja) 2023-02-21
CA2898128A1 (en) 2014-07-24
PL2945642T3 (pl) 2024-07-29
JP6809789B2 (ja) 2021-01-06
HK1215540A1 (en) 2016-09-02
RS65553B1 (sr) 2024-06-28
US20150352186A1 (en) 2015-12-10
WO2014111458A3 (en) 2014-09-12
FI2945642T3 (fi) 2024-05-10
EP3747457A3 (en) 2021-03-03
CN111100197A (zh) 2020-05-05

Similar Documents

Publication Publication Date Title
ES2986021T3 (es) Proteína factor 1 para la utilización en el tratamiento o prevención de enfermedades
JP7714710B2 (ja) アルブミン結合ドメイン融合タンパク質
ES2941965T3 (es) Nuevos receptores de linfocito T genomanipulados e inmunoterapias basadas en el uso de los mismos
ES2808153T3 (es) Terapia de combinación para tratamiento de enfermedad
JP7305543B2 (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
ES2916092T3 (es) Nuevos receptores de linfocitos T e inmunoterapias basadas en el uso de los mismos
CN105263958B (zh) p97片段及其应用
ES2938628T3 (es) Agentes de unión a VEGF/DLL4 y usos de los mismos
BR112021008204A2 (pt) novas composições de proteínas racionalmente projetadas
UA124577C2 (uk) Пептид для лікування раку
EA010726B1 (ru) Агенты, специфически связывающие ангиопоэтин-2
ES2939112T3 (es) Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario
ES2911663T3 (es) Anticuerpos humanos anti-IFN-alfa
TW202142254A (zh) 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子
KR20120105429A (ko) 염증 치료 방법
US11390666B2 (en) Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
JP2021518392A (ja) 二官能性血液脳治療
HK40042415A (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
HK40029335A (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
HK1215540B (en) Factor 1 protein for use in treating or preventing diseases
CN101017166A (zh) 人rtn4b蛋白在制备抗肿瘤药物中的应用
CN114929255A (zh) DKK3b的肽模拟物及使用方法